Published in AIDS Vaccine Week, November 29th, 2004
Revenue for the third quarter of 2004 was $2.4 million compared to $5.0 million for the third quarter of 2003. Revenue for the 9 months ended September 30, 2004 decreased to $6.5 million from $12.7 million for the same period of 2003.
Revenues in 2004 reflect amounts earned under the company's AIDS vaccine collaboration with the International AIDS Vaccine Initiative (IAVI) and the Columbus Children's Research Institute, which increased in 2004 compared to 2003, and to a lesser degree contract manufacturing revenue earned in the first quarter of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.